hotspot -WSS

hotspot

author：hotspot 2025-09-29 19:59:09 - browse：681

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Dramatically reducing cancer deaths requires the PASTEUR Act

entertainment

knowledge

WSS

First Opinion on colorectal cancer screening: letter and response

Researchers test human milk's ability to repair gut microbiome

Bird flu in dairy cattle: New measures to control spread to humans

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

White House drug shortage group privately met with industry

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Insurer loopholes limit power of law against surprise medical bills

In age of alternative facts, a scholarly course on calling out crap

Hundreds died while taking an arthritis drug, but nobody alerted patients

Bright Health sells Medicare Advantage business to Molina

For BCIs, commercial hurdles may be bigger than scientific ones

State Dept. review finds Biden bears some blame for Afghanistan failures

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

First Opinion on colorectal cancer screening: letter and response

hotspot

Pancreatic cancer is often deadly, but new discoveries are raising hope

Scientific mystery highlights the blind spots in genomics databases

White House drug shortage group privately met with industry

Drug companies' payments and gifts affect physicians' prescribing

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

Study: Black kids more likely to die after surgery than white kids

entertainment

Wikipedia

knowledge

leisure time